The company's metalized-DNA technology, known as M-DNA, has the potential to eliminate the need for amplification in many diagnostic tests, offering advantages such as ease of use, faster results, and lower costs. Adnavance Technologies aims to receive FDA approval for its simple and inexpensive platform, making it accessible for use in any laboratory. The company is also exploring applications of its technology in biosensor molecular diagnostics and energy generation management markets.